FWA
IOVA icon

FSC Wealth Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

FSC Wealth Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10
Closed – – 196
2022
Q3 		$0 Hold
10
– – ﹤0.01% 201
2022
Q2 		$0 Hold
10
– – ﹤0.01% 205
2022
Q1 		$0 Hold
10
– – ﹤0.01% 181
2021
Q4 		$0 Buy
+10
New +$220 ﹤0.01% 179

Other funds holding IOVA

State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

FSC Wealth Advisors's IOVA Position: Q4 2022 in Review

FSC Wealth Advisors sold out of Iovance Biotherapeutics (IOVA) in Q4 2022, closing a stake of 10 shares.

FSC Wealth Advisors first reported a position in IOVA in Q4 2021 and held it in 4 quarters. The position peaked at $0 in Q3 2022. 218 funds tracked by Wall St. Rank hold IOVA as of Q4 2022.

  • FSC Wealth Advisors reported no remaining Iovance Biotherapeutics position as of Q4 2022 after selling out during the quarter.
  • FSC Wealth Advisors sold 10 Iovance Biotherapeutics shares in Q4 2022.
  • FSC Wealth Advisors first reported a position in Iovance Biotherapeutics in Q4 2021 and held it in 4 quarters.
  • FSC Wealth Advisors's Iovance Biotherapeutics position peaked at $0 in Q3 2022.
  • 218 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2022.

Based on FSC Wealth Advisors's 13F filing for Q4 2022, filed 17 Jan 2023.